DanDan Dong

Dandan Dong, Ph.D., is a Managing Director of Vivo Capital with a background in academic biomedical science research and translational medicine. Dr. Dong is the founding team member of VISEN Pharmaceuticals and currently serves as VISEN’s Chief Business Officer. She has more than nine years’ experience in healthcare investments in both the United States and China. She has been involved in multiple transactions in both countries and cross-border deals. She is a managing member of Vivo PANDA Fund, Vivo’s early-stage investment vehicle. She has conducted research in infectious disease and immunology and published her research in multiple peer-reviewed journals, including Infection and Immunity, the Journal of Infectious Disease etc. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she has completed the Pre-doctoral Fellowship program at New York University School of Medicine.